Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04174105 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Minor2 versionsRe-verified since Jun 9, 2026, no change to tracked fieldsv22-v23
NotablePrimary and study completion dates: Feb 28, 2030 to Feb 28, 2035
Study description revised
v21
MinorRe-verified, no change to tracked fieldsv20
MinorEligibility criteria expanded, about 11 wordsv19
MinorTrial status: Recruiting to Active, Not Recruitingv18Show 4 more changesShow less
Enrollment target: estimated 18 to confirmed 11
Primary and study completion dates: Nov 30, 2029 to Feb 28, 2030
Eligibility criteria expanded, about 133 words
Site details revised at 4 of 4 sites
Show 16 earlier versionsHide 16 earlier versions
MinorRe-verified, no change to tracked fieldsv17
NotableEnrollment target: 12 to 18
Primary and study completion dates: Sep 30, 2029 to Nov 30, 2029
Eligibility criteria expanded, about 122 words
Secondary endpoints: 10 to 11
v16
MinorPrimary and study completion dates: Aug 31, 2029 to Sep 30, 2029v15
MinorPrimary and study completion dates: Apr 30, 2029 to Aug 31, 2029v14
MinorInterventions: AT845 (Genetic) to zocaglusagene nuzaparvovec (Genetic)v13
NotablePrimary completion date: May 31, 2025 to Apr 30, 2029
Study completion date: May 31, 2029 to Apr 30, 2029
v12
MinorPrimary completion date: Dec 31, 2024 to May 31, 2025
Study completion date: Nov 30, 2028 to May 31, 2029
v11
MinorEligibility criteria expanded, about 378 words
Secondary endpoints: details revised at 2 of 10 entries
Site contacts updated at 4 of 4 sites
v10
NotableTrial status: Active, Not Recruiting to Recruitingv9Show 4 more changesShow less
Primary completion date: Dec 2022 to Dec 31, 2024
Study sites: 6 to 4
Study completion date: Jan 2027 to Nov 30, 2028
Start date: Oct 28, 2020 to Oct 27, 2020
NotableLead sponsor: Audentes Therapeutics to Astellas Gene Therapies
Trial status: Recruiting to Active, Not Recruiting
Site details revised at 6 of 6 sites
v8
NotableEnrollment target: 8 to 12v7Show 5 more changesShow less
Study sites: 8 to 6
Secondary endpoints: 9 to 10
Primary endpoints revised (3)
Study description expanded, about 42 words
Study arms: 2 to 3
MinorSite details revised at 1 of 8 sitesv6
MinorSite contacts updated at 1 of 8 sitesv5
MinorStudy sites: 5 to 8
Start date changed from estimate of Aug 2020 to Oct 28, 2020
Secondary endpoints: details revised at 1 of 9 entries
Study description revised
v4
MinorStart date: Jul 2020 to Aug 2020
Site contacts updated at 1 of 5 sites
v3
NotableTrial status: Not Yet Recruiting to Recruitingv2Show 8 more changesShow less
Start date: Mar 2020 to Jul 2020
Primary endpoints revised (3)
Study sites: 0 to 5
Primary completion date: Mar 2023 to Dec 2022
Study completion date: Mar 2026 to Jan 2027
Eligibility criteria expanded, about 253 words
Secondary endpoints: 2 to 9
Study description expanded, about 116 words
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 1/2 open-label, ascending dose, multicenter clinical study to evaluate the safety and efficacy of AT845 in adult (aged ≥ 18 years) subjects, ambulatory or nonambulatory, with Late Onset Pompe Disease (LOPD).